| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_751e8522868a43324f760cd4c8d9010f |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6889 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00 |
| filingDate |
2005-06-09^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2009-06-02^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e5e394f58c6a36ed1b8e5a626075f757
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4efc6922d38eb3a57e744de2a41e40c3 |
| publicationDate |
2009-06-02^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-7541330-B2 |
| titleOfInvention |
Conjugates with reduced adverse systemic effects |
| abstract |
A conjugate of an active agent and a targeting moiety having affinity for a target cell, in which the active agent has been modified by attachment of a cell membrane-impermeabilizing group so that, if the active agent so modified is cleaved from the conjugate in the blood plasma instead of inside the target cell, the cell membrane-impermeabilizing group prevents or limits entry of the modified active agent into cells, thus reducing its systemic or non-specific adverse effects, including toxicity. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2012172412-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2011352204-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8426554-B2 |
| priorityDate |
2004-06-15^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |